“Clone-specific”antibody-drug conjugates:an innovative strategy in the treatment of T-cell cancers  

作　　者：Dennis Jungherz Philipp Lückemeier Marco Herling 

机构地区：[1]Department of Hematology,Cellular Therapy,Hemostaseology and Infectious Diseases,University of Leipzig Medical Center,Leipzig,Germany

出　　处：《Signal Transduction and Targeted Therapy》2024年第10期4149-4150,共2页信号转导与靶向治疗（英文）

基　　金：D.J.’s position is funded by the German JoséCarreras Leukemia Foundation(DJCLS 01 R/2023 to M.H.).P.L.is supported by the Clinician-Scientist program of the Medical Faculty of the University of Leipzig.The latter also provides the endowed professorship to M.H.

摘　　要：In a recent study published in Nature,Nichakawade et al.provided proof-of-principle data on innovative strategies to target and eliminate cancerous T-cells while sparing healthy T-lymphocytes,addressing the urgent clinical need posed by the mostly aggressive and treatment-refractory T-cell lymphomas.1 This research represents a significant milestone in overcoming major obstacles in immunotherapies for these cancers.

关 键 词：TREATMENT eliminate mostly 

分 类 号：R730.5[医药卫生—肿瘤]